Connors Investor Services Inc. lifted its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 0.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 74,500 shares of the company’s stock after acquiring an additional 601 shares during the period. Connors Investor Services Inc. owned approximately 0.20% of Omnicell worth $3,211,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Ameritas Investment Partners Inc. bought a new position in shares of Omnicell in the 1st quarter worth about $125,000. LS Investment Advisors LLC raised its position in shares of Omnicell by 136.3% in the 1st quarter. LS Investment Advisors LLC now owns 3,571 shares of the company’s stock worth $145,000 after acquiring an additional 2,060 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new position in shares of Omnicell in the 1st quarter worth about $170,000. Turner Investments LLC bought a new position in shares of Omnicell in the 2nd quarter worth about $181,000. Finally, Riverhead Capital Management LLC raised its position in shares of Omnicell by 76.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock worth $182,000 after acquiring an additional 1,830 shares in the last quarter. 96.35% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/omnicell-inc-omcl-shares-bought-by-connors-investor-services-inc/1580464.html.

In other Omnicell news, EVP Robin Gene Seim sold 9,780 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $48.97, for a total transaction of $478,926.60. Following the completion of the transaction, the executive vice president now owns 55,896 shares of the company’s stock, valued at $2,737,227.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gary S. Petersmeyer sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $51.73, for a total transaction of $51,730.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 180,562 shares of company stock valued at $8,914,801. 3.77% of the stock is owned by insiders.

Shares of Omnicell, Inc. (OMCL) traded up 0.82% during mid-day trading on Friday, reaching $48.90. The company had a trading volume of 31,813 shares. The company’s market capitalization is $1.83 billion. Omnicell, Inc. has a 12-month low of $30.35 and a 12-month high of $52.70. The firm has a 50-day moving average of $50.04 and a 200-day moving average of $43.64.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, July 27th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.02. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The company had revenue of $180.90 million during the quarter, compared to the consensus estimate of $174.08 million. During the same period in the prior year, the firm earned $0.38 earnings per share. Omnicell’s revenue was up 4.6% on a year-over-year basis. On average, equities analysts anticipate that Omnicell, Inc. will post $1.30 earnings per share for the current fiscal year.

Several research firms have recently weighed in on OMCL. Cantor Fitzgerald reissued an “overweight” rating and issued a $47.00 price objective (up from $43.00) on shares of Omnicell in a research report on Tuesday, June 13th. Dougherty & Co lifted their price objective on Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a research report on Friday, July 28th. Craig Hallum lifted their price objective on Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 28th. BidaskClub lowered Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Finally, Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $51.57.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.